Selegiline is ineffective in a collaborative double-blind, placebo- controlled trial for treatment of amyotrophic lateral sclerosis

Archives of Neurology

Volumn 55, Issue 1, 1998, Pages 93-96

  Lange, Dale J ^a   Murphy, Peregrine L ^b   Diamond, Beverly ^a   Appel, Vicki ^a   Lai, Eugene C ^a   Younger, David S ^a   Appel, Stanley H ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SELEGILINE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADMINISTRATION, ORAL; AMYOTROPHIC LATERAL SCLEROSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE INHIBITORS; SELEGILINE; TREATMENT OUTCOME;

EID: 0031886591     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.1.93     Document Type: Article

References (17)

1. Lange DJ, Murphy PL, Maxfield RA, Skarvala A, Reidel G. Management of patients with amyotrophic lateral sclerosis. J Neurol Rehab. 1994;8:21-28.
2. Rosen DR, Siddique T, Patterson D, et al. Mutations in the Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59-62.
3. Donaldson D, Fernando S. Murphy PL, et al. Blood superoxide dismutase, catalase, and glutathione peroxidase activity in amyotrophic lateral sclerosis. Neurology, 1995;45(suppl 4):221. Abstract.
4. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992;326:1464-1468.
5. Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol. 1981;10:499-505.
6. Westarp WE, Bartman P, Rossler J, et al. Antiretroviral therapy in sporadic adult amyotrophic lateral sclerosis. Neuroreport. 1993;4:819-822.
7. Smith RG, Hamilton HS, Hofmann F, et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med. 1992;327:1721-1728.
8. The Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1989;321:1364-1371.
9. Younger DS, Rowland LP, Latov N, et al. Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology. 1990;40:595-599.
10. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol. 1987;22:328-333.
11. Appel SH, Stewart SS, Appel V, et al. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol. 1988;45:381-386.
12. Cohen G, Spina MB. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. Ann Neurol. 1989;26:689-690.
13. Wiedau-Pazos M, Goto JJ, Rabizadeh S, et al. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 1996;171:515-517.
14. Knoll J. The pharmacology of selegiline ((-) deprenyl): new aspects. Acta Neurol Scand. 1989;126(suppl):83-91.
15. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, Ivy GO. (-)Deprenyl increases activities of superoxide dismutase and catalase in certain brain regions in old male mice. Life Sci. 1994;54:975-981.
16. Heinonen EH, Myllyla V, Sotaniemi K, et al. Pharmacokinetics and metabolism of selegiline. Acta Neurol Scand. 1989;126:93-99.
17. Havercamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population: validation of a scoring system and a model for survival prediction. Brain. 1995;118:707-719.